title: Properties of Ca(2+)-mediated inactivation of L-type Ca channel in smooth muscle cells of the guinea-pig urinary bladder.
abstract: The properties of Ca(2+)-mediated inactivation as revealed by a conventional double-pulse protocol were examined by using the whole-cell patch clamp technique. A U-shaped relationship between the conditioning potential and the Ca2+ current (ICa) inactivation was observed, with a maximum inactivation of 52 +/- 4% (n = 5) at 10 mV with 0.5 mM EGTA in the patch pipettes. The maximum inactivation was reduced significantly, to 31 +/- 5.7% (n = 12) and 32 +/- 7.0% (n = 5), when a high concentration of EGTA (20 mM) or a more efficient Ca2+ chelator, BAPTA, was included in the patch pipettes, respectively. The same double-pulse protocol was applied under conditions where the stored Ca2+ was depleted by using caffeine or the stored Ca2+ release function was blocked by using ryanodine or procaine and heparin. No significant difference in the maximum ICa inactivation before (45%) and after (50%) application of 10 mM caffeine was observed. The maximum ICa inactivations of 48 +/- 3.2% (n = 4) and 52 +/- 8.4% (n = 6) were still observed after treatment of the cell with ryanodine (20 microM) or loading 10 mM procaine and 1 mg/mL heparin in the patch pipettes, respectively. These results suggest that Ca2+ mobilization from an internal Ca2+ store is not essential for the Ca(2+)-mediated inactivation observed in the double-pulse experiment, rather influx of Ca2+ through a voltage-dependent Ca channel seems to be important for ICa inactivation.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Physiology, Sapporo Medical University, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Yoshino
authors.forename: Y
authors.initials: Y
authors.lastname: Matsufuji
authors.forename: H
authors.initials: H
authors.lastname: Yabu
mesh_terms: D000818:Animals; D002110:Caffeine / Q000494:pharmacology; D002118:Calcium / Q000494:pharmacology*; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D015220:Calcium Channels / Q000187:drug effects / Q000378:metabolism*; D004533:Egtazic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D004594:Electrophysiology; D006168:Guinea Pigs; D006493:Heparin / Q000494:pharmacology; D066298:In Vitro Techniques; D008297:Male; D009130:Muscle, Smooth / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D018408:Patch-Clamp Techniques; D011343:Procaine / Q000494:pharmacology; D012433:Ryanodine / Q000494:pharmacology; D001743:Urinary Bladder / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*
chemical_list: D002121:Calcium Channel Blockers; D015220:Calcium Channels; D012433:Ryanodine; D002110:Caffeine; D011343:Procaine; D004533:Egtazic Acid; D006493:Heparin; C025603:1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid; D002118:Calcium